OCON Therapeutics
Our mission is to introduce an innovative,
high-quality intrauterine drug-delivery technology
to improve and impact women’s health and quality of life
OCON Healthcare
Our mission is to introduce an innovative, high-quality intrauterine drug-delivery technology to improve and impact women’s health and quality of life
This Is What We Do
OUR PRODUCTS
IUB® BALLERINE®, a safer1, hormone-free next generation “smart” IUD (long acting reversible contraceptive) that fits women’s anatomy.
IUB® SEAD® (Spherical Endometrial Ablation Device), is a new paradigm in the treatment of Abnormal Uterine Bleeding (AUB) & Heavy Menstrual Bleeding (HMB): a novel, once-and-done, pain-free2 and safe solution.
IUB® PRIMA®, a therapeutic-delivery to target therapy areas such as endometriosis and myomas as well as heavy menstrual bleeding and other hormonal solutions delivered directly through the uterus moving away from systemic side effects.
The World Economic Forum recognizes OCON Therapeutics as Technology Pioneer for creating new technologies and innovation that are poised to have a significant impact on business and society.
why ocon?
Finally, women’s health products that are designed and managed by women for women that fit women’s anatomy and needs.
OCON’s platform technology excels in simplicity, safety, cost-effectiveness, new and innovative technology.
in the media
OCON Therapeutics Secures $10M in Funding to Revolutionize Women’s Health with Advanced Drug Delivery Solutions
June 24, 2024
|
Femtech Insider
OCON Therapeutics has been awarded the 2024 Seal of Excellence from the EU Commission – recognizing top-tier innovative ideas worthy of investment – for its IUB® Platform’s innovative nature and potential to drive meaningful change for women and families in the EU and globally.
April 3, 2024
|
EU Commission
1 compared to literature of Traditional IUDs and ongoing vigilance reporting for IUB® BALLERINE®, OCON Medical Ltd.
2 ongoing Phase II Clinical Studies, OCON Medical Ltd.